ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

People

Trevor C. McMorris

by Susan J. Ainsworth
July 15, 2013 | APPEARED IN VOLUME 91, ISSUE 28

McMorris
[+]Enlarge
09128-peopobits-McMorrisLJLightcxd.jpg

Trevor C. McMorris, 82, a professor emeritus of chemistry and biochemistry at the University of California, San Diego, died on Feb. 19. He had Parkinson’s disease.

Born in Kingston, Jamaica, McMorris earned a B.Sc. in chemistry, physics, and mathematics in 1952 as part of the first graduating class of the University of the West Indies, in Mona, Jamaica. He received a Ph.D. in organic chemistry from Imperial College London in 1958 and was a postdoctoral fellow at Imperial College and the University of Western Ontario.

McMorris then accepted a research position at the New York Botanical Garden in 1960 before joining the UCSD chemistry and biochemistry faculty as an associate professor in 1973.

Focusing his research on the design and synthesis of analogs of natural substances, he studied the antitumor agent illudin and the plant hormone brassinolide. McMorris was the first to synthesize irofulven, an analog of illudin, which was developed as a possible cure for pancreatic cancer by MGI Pharma (now part of Eisai Pharmaceuticals). He retired in 2001.

McMorris’ first wife, Helen, died in 1981. He is survived by his wife of 28 years, Georgette; four stepsons; and seven stepgrandchildren.

Obituary notices of no more than 300 words may be sent to Susan J. Ainsworth at s_ainsworth@acs.org and should include an educational and professional history.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment